NETRF welcomes two leaders to its Board of Directors. Julie Mebane, Partner, Duane Morris, LLP, and Laurie Rains, Senior Vice President, U.S. Retail Services, Convenience and Liquor Channels, Neilsen. Learn how these new Board members hope to help those living with NETs. (MORE)
NETRF reports progress in the development of neuroendocrine tumor cell lines to help eliminate a decades-old obstacle in laboratory research. To stimulate progress in NET cell lines, NETRF established a Cell Line Prize, funded cell line research, and launched a collaboration with a nationally known research institute. Each of these initiatives has succeeded in establishing NET cell lines.
NETRF welcomes five new members to its Board of Scientific Advisors, a volunteer council of highly distinguished medical and research leaders who share NETRF’s commitment to advancing the diagnosis and treatment of neuroendocrine cancer.
A NETRF-funded clinical trial looks at a cancer vaccine called SurVaxM in neuroendocrine cancer to help slow or stop the spread of neuroendocrine tumors.